Georgia Chondrou, George Philippidis, Panagiotis Georgakopoulos, Evaggelos Mavrommatis
{"title":"下肢血管重建术后的西洛他唑效应。历史背景与文献回顾。","authors":"Georgia Chondrou, George Philippidis, Panagiotis Georgakopoulos, Evaggelos Mavrommatis","doi":"10.26574/maedica.2023.18.4.665","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction:</b> Cilostazol is a selective cyclic inhibitor of the 3-phosphodiesterase type (PDE3) that is recommended to be administered in cases of symptomatic peripheral vascular disease (YEI). It was discovered as a chemical compound in the 1980s, in Takao Nishi laboratory in Japan. <b>Objective:</b> The purpose of the present review was to evaluate the efficacy of cilostazol administration in a YEI with intermittent claudication or moderate to severe lower extremity ischemia. <b>Materials and methods:</b>A systematic review of the literature was carried out where articles were searched in the international database PubMed. The year 2005 was set as a time limit for the publication date of the articles. The following keywords were used: cilostazol, peripheral arterial disease, revascularization and lower limb. A total of 95 articles were found, of which only 10 were selected for the present study. <b>Results:</b>According to the results of the current review, the use of cilostazol increases the ability to walk, improves the quality of life, reduces the rates of re-narrowing of vessels and stents, reduces the likelihood of amputation and is co-administered with other antiplatelet and anticoagulant agents. <b>Conclusion:</b>Cilostazol administration should be a possible treatment option for symptomatic YEI. Further research is necessary to determine its safety after three years.</p>","PeriodicalId":74094,"journal":{"name":"Maedica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10859191/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cilostazol Effects after Lower Extremity Revascularization. Historical Background and Review of the Literature.\",\"authors\":\"Georgia Chondrou, George Philippidis, Panagiotis Georgakopoulos, Evaggelos Mavrommatis\",\"doi\":\"10.26574/maedica.2023.18.4.665\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Introduction:</b> Cilostazol is a selective cyclic inhibitor of the 3-phosphodiesterase type (PDE3) that is recommended to be administered in cases of symptomatic peripheral vascular disease (YEI). It was discovered as a chemical compound in the 1980s, in Takao Nishi laboratory in Japan. <b>Objective:</b> The purpose of the present review was to evaluate the efficacy of cilostazol administration in a YEI with intermittent claudication or moderate to severe lower extremity ischemia. <b>Materials and methods:</b>A systematic review of the literature was carried out where articles were searched in the international database PubMed. The year 2005 was set as a time limit for the publication date of the articles. The following keywords were used: cilostazol, peripheral arterial disease, revascularization and lower limb. A total of 95 articles were found, of which only 10 were selected for the present study. <b>Results:</b>According to the results of the current review, the use of cilostazol increases the ability to walk, improves the quality of life, reduces the rates of re-narrowing of vessels and stents, reduces the likelihood of amputation and is co-administered with other antiplatelet and anticoagulant agents. <b>Conclusion:</b>Cilostazol administration should be a possible treatment option for symptomatic YEI. Further research is necessary to determine its safety after three years.</p>\",\"PeriodicalId\":74094,\"journal\":{\"name\":\"Maedica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10859191/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Maedica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26574/maedica.2023.18.4.665\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Maedica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26574/maedica.2023.18.4.665","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cilostazol Effects after Lower Extremity Revascularization. Historical Background and Review of the Literature.
Introduction: Cilostazol is a selective cyclic inhibitor of the 3-phosphodiesterase type (PDE3) that is recommended to be administered in cases of symptomatic peripheral vascular disease (YEI). It was discovered as a chemical compound in the 1980s, in Takao Nishi laboratory in Japan. Objective: The purpose of the present review was to evaluate the efficacy of cilostazol administration in a YEI with intermittent claudication or moderate to severe lower extremity ischemia. Materials and methods:A systematic review of the literature was carried out where articles were searched in the international database PubMed. The year 2005 was set as a time limit for the publication date of the articles. The following keywords were used: cilostazol, peripheral arterial disease, revascularization and lower limb. A total of 95 articles were found, of which only 10 were selected for the present study. Results:According to the results of the current review, the use of cilostazol increases the ability to walk, improves the quality of life, reduces the rates of re-narrowing of vessels and stents, reduces the likelihood of amputation and is co-administered with other antiplatelet and anticoagulant agents. Conclusion:Cilostazol administration should be a possible treatment option for symptomatic YEI. Further research is necessary to determine its safety after three years.